<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263039</url>
  </required_header>
  <id_info>
    <org_study_id>NL61719.056.17</org_study_id>
    <nct_id>NCT03263039</nct_id>
  </id_info>
  <brief_title>Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab</brief_title>
  <acronym>RESPONDER</acronym>
  <official_title>Biomarker Discovery Study to Identify Patients With Advanced Urothelial Cancer Benefitting From Pembrolizumab Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the RESPONDER study, the role of the immune evasive mechanisms combined with genomic
      characterization will be explored in urothelial cancer patients treated with second-line
      treatment with pembrolizumab.

      Combined profiling of immune and molecular status is novel and may contribute to improved
      patient stratification and provide rationale for future treatment strategies containing
      pembrolizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antibodies that target the crosstalk between immune and cancer cells by inhibiting programmed
      death 1 (PD-1, pembrolizumab and durvalumab) or programmed death-ligand 1 (PD-L1,
      atezolizumab) have shown promising results as second-line treatments in phase II studies with
      response rates of about 30%.

      Although urothelial cancer is prone to immune checkpoint blockade, better understanding of
      the underlying mechanisms is necessary to improve patient selection. The efficacy of immune
      checkpoint inhibitors in urothelial cancer may be affected by both tumor specific and
      environmental factors. In order to improve the efficacy of immunotherapy in urothelial
      cancer, drivers of local immune suppression need to be identified.

      In this prospective translational multicenter study, clinical data, peripheral blood and
      sequential tumor biopsies are collected from urothelial cancer patients treated with
      second-line treatment with pembrolizumab to identify the role of immune evasive mechanisms
      combined with genomic characterization. A pre-treatment tumor biopsy and blood sample will be
      obtained and subsequently whole genome sequencing and whole genome RNA sequencing is
      performed. Both tumor tissue as well as peripheral blood will be investigated for immune and
      molecular profiling. A biopsy will also be taken after start of treatment (at 6 weeks) and at
      progression (optional)

      For future research projects, longitudinal blood samples will be collected for isolation of
      immune cells, cytokine/chemo-attractants and circulating tumor DNA (ctDNA).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Anticipated">August 21, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers in patients with clinical benefit</measure>
    <time_frame>End of study (pembrolizumab will be given for a maximum of 24 months), which is within 3 years after start of inclusion</time_frame>
    <description>Peripheral blood and sequential tumor biopsies are collected before start of treatment, during treatment, and (optionally) at progression.
Immune profiling using in situ multiplex immunofluorescence will be performed to identify tumor epithelial and stromal cells, effector immune cells, T cell co-inhibition, T cell recruitment and immune-suppressive cells. Furthermore, serum samples will be assessed for levels of cytokines/chemoattractants. Finally, longitudinal blood samples will be collected for isolation of immune cells, cytokine/chemo-attractants and ctDNA.
A qualified pathologist will determine tumor cell percentage in the obtained biopsies. DNA will be obtained from both cancer cells (biopsy tissue) and normal white blood cells (peripheral blood) and will be submitted for whole genome sequencing.
The obtained data will contribute to identifying potential biomarkers in patients with clinical benefit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mechanisms of primary and acquired resistance to pembrolizumab</measure>
    <time_frame>End of study (pembrolizumab will be given for a maximum of 24 months), which is anticipated to be within 3 years after start inclusion.</time_frame>
    <description>Combined profiling of immune and molecular status (as described in outcome 1) during treatment and at disease progression will reveal different mechanisms by which urothelial cancer evades pembrolizumab.
Additional bio-informatic analyses will be done to detect the somatic structural variants and copy number changes. The genome data will be used to explore potential correlations between specific pathway aberrations, total number of somatic variants and pattern of mutational load characteristic of the DNA mutational agent and clinical outcome. Moreover, we will perform whole genome RNA sequencing, an essential part of the genomic analysis to identify tumor specific neo-antigens.
The obtained data will contribute to identifying mechanisms of primary and acquired resistance to pembrolizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between biomarkers and clinical activity</measure>
    <time_frame>End of study (pembrolizumab will be given for a maximum of 24 months), which is anticipated to be within 3 years after start inclusion.</time_frame>
    <description>The following definitions and response evaluation criteria will be used to assess potential correlation: immune related response criteria (irRC), duration of response according to RECIST and irRC, duration of clinical benefit (CR-complete response/PR-partial response/SD-stable disease) according to RECIST and irRC, progression-free survival, and overall survival.
By combining the data from the profiling of immune and molecular status (as described in outcome 1) with the additional data from bio-informatic analyses (as described in outcome 2) and the clinical activity (as described above), correlations between biomarkers and clinical activity can be identified.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Translation experiments</measure>
    <time_frame>Collection of samples will be until end of study (pembrolizumab will be given for a maximum of 24 months), which is anticipated to be within 3 years after start inclusion.</time_frame>
    <description>To collect tissue, blood and urine samples for future translational experiments</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Transitional Cell Carcinoma of the Bladder</condition>
  <condition>Biomarkers</condition>
  <arm_group>
    <arm_group_label>Treatment with pembrolizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pembrolizumab will be administered at a flat dose of 200 mg as a 30 minute (-5 min/+10 min) IV infusion every 3 weeks (Q3W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg Q3W</description>
    <arm_group_label>Treatment with pembrolizumab</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Should have signed informed consent for CPCT-02 (this is another clinical trial,
             NCT01855477)

          2. Be willing and able to provide written informed consent for the trial.

          3. Be &gt;= 18 years of age on day of signing informed consent.

          4. Have histologically or cytologically-confirmed urothelial cancer that is not amenable
             to curative treatment with local and/or systemic therapies.

          5. Have progressive disease after platinum containing chemotherapy as defined by:

               1. Disease progression after treatment with a platinum-containing regimen for
                  recurrent (disease not amenable to curative treatment)/metastatic disease

               2. Recurrence/progression within 12 months of prior therapy containing platinum

          6. Have measurable disease based on RECIST 1.1. Tumor lesions located in a previously
             irradiated area are considered measurable if progression has been demonstrated in
             these lesions.

          7. Be willing to provide tissue from a newly obtained core or excisional biopsy of a
             tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days)
             prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples
             cannot be provided (e.g. inaccessible or subject safety concern) may submit an
             archived specimen only upon agreement from the Sponsor.

          8. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Scale.

          9. Demonstrate adequate organ function according to screening labs, which should be
             performed within 10 days of treatment initiation.

         10. Female subject of childbearing potential should have a negative urine or serum
             pregnancy within 72 hours prior to receiving the first dose of study medication. lf
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test
             will be required.

         11. Female subjects of childbearing potential must be willing to use an adequate method of
             contraception as outlined in protocol - Contraception, for the course of the study
             through 120 days after the last dose of study medication.

             Note: Abstinence is acceptable if this is the usual lifestyle and preferred
             contraception for the subject.

         12. Male subjects of childbearing potential must agree to use an adequate method of
             contraception as outlined in protocol- Contraception, starting with the first dose of
             study therapy through 120 days after the last dose of study therapy.

        Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception
        for the subject.

        Exclusion Criteria:

          1. Treamtent with an investigational agent and received study therapy or used an
             investigational device within 4 weeks of the first dose of treatment.

          2. Has a diagnosis of immunodeficiency or is receiving high dose systemic steroid therapy
             (defined as &gt;=; 20 mg prednisone or equivalent per day) or any other form of
             immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

          3. Has a known history of active TB (Tuberculosis Bacillus).

          4. Hypersensitivity to pembrolizumab or any of its excipients.

          5. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study
             Day 1 or who has not recovered (i.e., :S Grade 1 or at baseline) from adverse events
             due to agents administered more than 4 weeks earlier.

          6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks prior to study Day 1 or who has not recovered (i.e., :S Grade 1 or at
             baseline) from adverse events due to a previously administered agent

               -  Note: Subjects with Grade 2 neuropathy are an exception to this criterion and may
                  qualify for the study.

               -  Note: If subject received major surgery, they must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting
                  therapy.

          7. Has a known additional malignancy that is progressing or requires active treatment
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer.

          8. Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             high dose steroids (defined as &gt;=; 20 mg prednisone or equivalent per day) for at
             least 7 days prior to trial treatment. This exception does not include carcinomatous
             meningitis which is excluded regardless of clinical stability.

          9. Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.

         10. Has known history of, or any evidence of active, (non-infectious) pneumonitis that
             required steroids, evidence of interstitial lung disease or active, non-infectious
             pneumonitis.

         11. Has an active infection requiring systemic therapy.

         12. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subjects
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

         13. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         14. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the prescreening or screening visit
             through 120 days after the last dose of trial treatment.

         15. Has received prior therapy with an anti-PD-1, anti-PD-L 1, or anti- PD-L2 agent.

         16. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

         17. Has a known history ofor is positive for hepatitis B (hepatitis B surface antigen
             [HBsAg] reactive) or hepatitis C (hepatitis C virus [HCV] RNA [qualitative] is
             detected). Note: Without known history, testing needs to be performed to determine
             eligibility.

             Hepatitis C antibody (Ab) testing is allowed for screening purposes in countries where
             HCV RNA is not part of standard of care.

         18. Has received a live vaccine within 30 days of planned start of study therapy. Note:
             Seasonal influenza vaccines for injection are generally inactivated flu vaccines and
             are allowed; however intranasal influenza vaccines (e.g., Flu-MistÂ®) are live
             attenuated vaccines, and are not allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M.P.J.K. Lolkema</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A.A.M. van der Veldt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soumia Aammari</last_name>
    <phone>0031107042129</phone>
    <email>responder@erasmusmc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ilse Oosterom</last_name>
    <email>responder@erasmusmc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soumia Aammari</last_name>
      <email>responder@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ilse Oosterom</last_name>
      <email>responder@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>August 23, 2017</last_update_submitted>
  <last_update_submitted_qc>August 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>M.P.J.K. Lolkema</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Programmed Cell Death 1 Receptor</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Keytruda</keyword>
  <keyword>MK-3475</keyword>
  <keyword>Urothelial Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Information can be shared by importing it into another databases</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

